Article

WaveLight signs agreement with Oculus to market Oculyzer pentacam

WaveLight Inc. announced a joint agreement with German-based Oculus GmbH to sell the Oculus Pentacam under the brand name Oculyzer in conjunction with the Allegretto Wave family of products.

Chicago-WaveLight Inc. announced a joint agreement with German-based Oculus GmbH to sell the Oculus Pentacam under the brand name Oculyzer in conjunction with the Allegretto Wave family of products.

WaveLight will now offer two topography-guided systems, both of which are manufactured by Oculus. The Allegro Topolyzer produces eight reproducible topographic maps and delivers customized Allegretto Wave treatments through its T-CAT diagnostic interface. The Allegro Oculyzer features a wider array of diagnostic capabilities than the Topolyzer, including a Scheimpflug camera that provides five critical measurements of the anterior segment of the eye, as well as detailed central corneal data. It is also designed to be integrated with the Allegretto Wave through its exclusive OcuLink software interface.

The Oculyzer will be available for sale internationally in 2006, with the addition of the OcuLink anticipated in late spring. The agreement between WaveLight and Oculus will also permit the Oculyzer to be sold as a diagnostic tool for U.S. customers. While U.S. clinical studies have not been initiated using the Oculyzer, the company said it is planning to commence topography-guided clinical trials with the Topolyzer system soon.

More information is available at the WaveLight Booth 3250.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.